SCHEDULE 13G: Third Rock Ventures Discloses Significant Stake in Maze Therapeutics

Third Rock Ventures entities have filed a Schedule 13G, revealing beneficial ownership of 16.1% of Maze Therapeutics, Inc.'s common stock as of January 31, 2025.

Summary

• Third Rock Ventures IV, L.P., along with its general partners (Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC), beneficially owns 6,073,958 shares of Maze Therapeutics, Inc. common stock, representing approximately 13.9% of the class.
• Third Rock Ventures V, L.P., along with its general partners (Third Rock Ventures GP V, L.P. and TRV GP V, LLC), beneficially owns an additional 950,800 shares of Maze Therapeutics, Inc. common stock, representing approximately 2.2% of the class.
• The combined beneficial ownership by Third Rock Ventures entities totals 7,024,758 shares, equating to approximately 16.1% of the outstanding common stock.
• The percentage of class was calculated based on 43,796,057 shares of common stock issued and outstanding as of March 25, 2025, as disclosed in Maze Therapeutics' 10-K filing on March 31, 2025.
• All reported shares are held with shared voting power and shared dispositive power among the respective Third Rock Ventures entities.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it confirms a significant and continued investment by a reputable venture capital firm in Maze Therapeutics, indicating ongoing confidence. However, it's a routine disclosure, not new news of an investment.

Positives

• The disclosure confirms a significant and continued investment by Third Rock Ventures, a prominent venture capital firm specializing in life sciences, which can be interpreted as a vote of confidence in Maze Therapeutics' long-term prospects.

Risks

• The reporting persons explicitly disclaim the existence of a 'group' for purposes of Rule 13d-5 of the Securities Exchange Act of 1934, as amended, which is a standard legal disclaimer to avoid potential regulatory implications associated with acting as a coordinated group.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates that Third Rock Ventures, a venture capital firm focused on the life sciences, maintains a significant ownership stake in Maze Therapeutics, Inc. Such filings are common for institutional investors who acquire more than 5% of a company's stock, providing transparency into major shareholder positions. For biotechnology companies like Maze Therapeutics, the continued backing of specialized venture capital firms can signal ongoing support and belief in the company's long-term potential and pipeline development.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can influence investor perception and confidence. The continued presence of a major venture capital firm as a significant shareholder may be viewed positively.

Key Dates

Keywords

Maze Therapeutics, Third Rock Ventures, SEC filing, Schedule 13G, Beneficial ownership, Common Stock, Institutional ownership, Venture Capital, Biotechnology, Life Sciences